In this study, the reasons for the association with serum CRP levels and the efficacy of nivolumab remain unclear, but serum CRP and IL-6 levels have previously been shown to predict tumor response and survival to immunotherapy, such as high dose IL-2, IFN alpha, and ipilimumab [41–44]. This evidence concerns the gene CRP and neoplasm.